Global Statin Market (2019-2023) is Forecast to Register a CAGR of Over 2% - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 7, 2018--The “Global Statin Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.
The statin market will register a CAGR of over 2% by 2023.
The increasing statin use will help the market grow at a steady rate. In the US and the UK, people aged 40 and above are recommended to monitor their cholesterol level. Statins are considered an evidence-based treatment for high risk patients with elevated cardiovascular disorder.
Rising prevalence of hypercholesterolemia
The rising prevalence of hypercholesterolemia is fueling the demand for generic cholesterol medications. Cardiovascular disease is one of the primary causes of mortality in Western countries.
Fierce generic competition
Patient expiration is a major challenge for companies developing branded drugs as it provides an opportunity for the development of generic drugs.
Key PlayersAstraZeneca Merck Novartis Pfizer
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPEMarket ecosystem Market characteristics Market segmentation analysis Pipeline
PART 04: MARKET SIZINGMarket definition Market sizing 2018 Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSISBargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition
PART 06: MARKET SEGMENTATION BY TYPEMarket segmentation by type Comparison by type Synthetic statins - Market size and forecast 2018-2023 Natural statins - Market size and forecast 2018-2023 Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: MARKET SEGMENTATION BY APPLICATIONDyslipidemia Others
PART 09: GEOGRAPHIC LANDSCAPEGeographic segmentation Geographic comparison Americas - Market size and forecast 2018-2023 EMEA - Market size and forecast 2018-2023 APAC - Market size and forecast 2018-2023 Key leading countries Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGESMarket drivers Market challenges
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPEOverview Landscape disruption
PART 14: VENDOR ANALYSISVendors covered Vendor classification Market positioning of vendors AstraZeneca Merck Novartis Pfizer
For more information about this report visit https://www.researchandmarkets.com/research/nv3v3x/global_statin?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181207005430/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Cardiovascular Drugs
INDUSTRY KEYWORD: HEALTH CARDIOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 12/07/2018 12:49 PM/DISC: 12/07/2018 12:49 PM